Update on the Treatment of Acute Myelogenous Leukemia (AML)

Listen Now

Topics Covered

• Overview of Acute Myelogenous Leukemia (AML), in the Context of COVID-19
• Current Treatment Options
• Transplantation as a Treatment Option for AML
• New & Emerging Therapies
• The Role of Clinical Trials, in the Context of COVID-19
• How Clinical Trials Increase Treatment Options
• Side Effect, Symptom & Pain Management Tips, in the Context of COVID-19
• Important Questions to Ask When Communicating with Your Health Care Team
• The Increasing Role of Telehealth/Telemedicine Appointments
• Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology & List of Prepared Questions
• Quality-of-Life Concerns & Follow-Up Care
• Questions for Our Panel of Experts

Our Panel of Experts

Farhad Ravandi, MD

Janiece and Stephen A. Lasher Professor of Medicine, Chief, Section of Departmental Therapeutics, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Eytan M. Stein, MD

Hematologic Oncologist, Clinical Trialist, Acute Myeloid Leukemia, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center

Carrie Callas

Director of Programs, Leukemia Research Foundation

Carolyn Messner, DSW, BCD, FAPOS, FAOSW

Director of Education and Training, CancerCare

Brochure

You can download the brochure for this workshop

Workshop Date

This workshop was originally recorded on June 11, 2021.